Lehman Downgrades Telik

Analyst Jim Birchenough believes the pharmaceutical company's non-small cell lung cancer product may have a limited upside

Lehman downgrades Telik Inc. (TELK ) to equal-weight from overweight.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.